Proficio Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $232K | Buy |
1,065
+31
| +3% | +$6.88K | 0.01% | 227 |
|
|
2025
Q4 | $236K | Sell |
1,034
-146
| -12% | -$33.3K | 0.02% | 218 |
|
|
2025
Q3 | $273K | Sell |
1,180
-5,847
| -83% | -$1.19M | 0.02% | 186 |
|
|
2025
Q2 | $1.3M | Buy |
7,027
+118
| +2% | +$21.9K | 0.08% | 134 |
|
|
2025
Q1 | $1.45M | Buy |
6,909
+287
| +4% | +$55.8K | 0.11% | 100 |
|
|
2024
Q4 | $1.18M | Buy |
6,622
+2,230
| +51% | +$410K | 0.1% | 91 |
|
|
2024
Q3 | $867K | Sell |
4,392
-1,494
| -25% | -$279K | 0.09% | 106 |
|
|
2024
Q2 | $1.01M | Sell |
5,886
-514
| -8% | -$85.1K | 0.11% | 104 |
|
|
2024
Q1 | $1.17M | Buy |
6,400
+587
| +10% | +$101K | 0.13% | 96 |
|
|
2023
Q4 | $901K | Sell |
5,813
-167
| -3% | -$24.3K | 0.11% | 100 |
|
|
2023
Q3 | $891K | Buy |
5,980
+345
| +6% | +$50.6K | 0.12% | 92 |
|
|
2023
Q2 | $759K | Sell |
5,635
-868
| -13% | -$127K | 0.1% | 112 |
|
|
2023
Q1 | $1.04M | Buy |
6,503
+395
| +6% | +$60.4K | 0.16% | 81 |
|
|
2022
Q4 | $987K | Buy |
6,108
+733
| +14% | +$112K | 0.19% | 76 |
|
|
2022
Q3 | $721K | Buy |
5,375
+98
| +2% | +$14.1K | 0.13% | 92 |
|
|
2022
Q2 | $808K | Buy |
5,277
+408
| +8% | +$62.3K | 0.15% | 85 |
|
|
2022
Q1 | $789K | Sell |
4,869
-895
| -16% | -$130K | 0.12% | 94 |
|
|
2021
Q4 | $781K | Buy |
5,764
+149
| +3% | +$17.6K | 0.11% | 109 |
|
|
2021
Q3 | $606K | Sell |
5,615
-116
| -2% | -$13.3K | 0.08% | 128 |
|
|
2021
Q2 | $646K | Sell |
5,731
-227
| -4% | -$25.6K | 0.08% | 119 |
|
|
2021
Q1 | $645K | Buy |
5,958
+472
| +9% | +$50.5K | 0.08% | 107 |
|
|
2020
Q4 | $588K | Buy |
5,486
+382
| +7% | +$36.7K | 0.09% | 88 |
|
|
2020
Q3 | $420K | Buy |
5,104
+326
| +7% | +$30.7K | 0.07% | 104 |
|
|
2020
Q2 | $469K | Buy |
4,778
+1,148
| +32% | +$101K | 0.1% | 90 |
|
|
2020
Q1 | $261K | Buy |
+3,630
| New | +$309K | 0.07% | 124 |
|
|
2019
Q3 | – | Sell |
-1,915
| Closed | -$139K | – | 125 |
|
|
2019
Q2 | $139K | Buy |
1,915
+143
| +8% | +$11.2K | 0.05% | 169 |
|
|
2019
Q1 | $143K | Buy |
1,772
+271
| +18% | +$22.2K | 0.05% | 159 |
|
|
2018
Q4 | $138K | Buy |
1,501
+86
| +6% | +$7.56K | 0.06% | 134 |
|
|
2018
Q3 | $134K | Sell |
1,415
-33
| -2% | -$3.13K | 0.04% | 165 |
|
|
2018
Q2 | $134K | Buy |
1,448
+95
| +7% | +$9.28K | 0.06% | 170 |
|
|
2018
Q1 | $128K | Sell |
1,353
-1,966
| -59% | -$216K | 0.04% | 176 |
|
|
2017
Q4 | $321K | Buy |
3,319
+41
| +1% | +$3.86K | 0.1% | 102 |
|
|
2017
Q3 | $291K | Sell |
3,278
-65
| -2% | -$4.95K | 0.12% | 108 |
|
|
2017
Q2 | $236K | Sell |
3,343
-144
| -4% | -$9.68K | 0.1% | 149 |
|
|
2017
Q1 | $230K | Buy |
3,487
+969
| +38% | +$60.9K | 0.1% | 136 |
|
|
2016
Q4 | $158K | Sell |
2,518
-201
| -7% | -$12.3K | 0.07% | 149 |
|
|
2016
Q3 | $171K | Buy |
2,719
+43
| +2% | +$2.78K | 0.1% | 140 |
|
|
2016
Q2 | $173K | Buy |
2,676
+376
| +16% | +$22.9K | 0.11% | 137 |
|
|
2016
Q1 | $131K | Buy |
2,300
+2,008
| +688% | +$112K | 0.11% | 124 |
|
|
2015
Q4 | $17K | Buy |
+292
| New | +$16.8K | 0.02% | 207 |
|
Other funds holding ABBV
VCM
VPM
Proficio Capital Partners's ABBV Position: Q1 2026 in Review
Proficio Capital Partners increased its AbbVie (ABBV) stake by 3% in Q1 2026, buying an estimated $6.88K and bringing the position to 1,065 shares worth $232K. The position accounts for 0.01% of the portfolio, ranked #227.
Proficio Capital Partners first reported a position in ABBV in Q4 2015 and has held it in 40 quarters since. The position peaked at $1.45M in Q1 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Proficio Capital Partners held 1,065 shares of AbbVie worth $232K as of Q1 2026.
- Proficio Capital Partners bought 31 AbbVie shares in Q1 2026, an estimated $6.88K.
- AbbVie made up 0.01% of Proficio Capital Partners's portfolio in Q1 2026, its #227 holding.
- Proficio Capital Partners first reported a position in AbbVie in Q4 2015 and has held it in 40 quarters since.
- Proficio Capital Partners's AbbVie position peaked at $1.45M in Q1 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Proficio Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.